These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38308295)

  • 21. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.
    Bodensteiner D; Scott CR; Sims KB; Shepherd GM; Cintron RD; Germain DP
    Genet Med; 2008 May; 10(5):353-8. PubMed ID: 18496035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α.
    Tsuboi K; Yamamoto H
    Genet Med; 2014 Oct; 16(10):766-72. PubMed ID: 24651606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
    Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
    Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
    Linhart A; Dostálová G; Nicholls K; West ML; Tøndel C; Jovanovic A; Giraldo P; Vujkovac B; Geberhiwot T; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Hughes D
    Orphanet J Rare Dis; 2023 Oct; 18(1):332. PubMed ID: 37865771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
    Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
    Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
    Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
    J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.
    Krämer J; Lenders M; Canaan-Kühl S; Nordbeck P; Üçeyler N; Blaschke D; Duning T; Reiermann S; Stypmann J; Brand SM; Gottschling T; Störk S; Wanner C; Sommer C; Brand E; Weidemann F
    Nephrol Dial Transplant; 2018 Aug; 33(8):1362-1372. PubMed ID: 29186537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
    Tsuboi K; Yamamoto H
    Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22498845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.
    Ortiz A; Abiose A; Bichet DG; Cabrera G; Charrow J; Germain DP; Hopkin RJ; Jovanovic A; Linhart A; Maruti SS; Mauer M; Oliveira JP; Patel MR; Politei J; Waldek S; Wanner C; Yoo HW; Warnock DG
    J Med Genet; 2016 Jul; 53(7):495-502. PubMed ID: 26993266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
    Tsuboi K; Yamamoto H
    Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22878505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.
    Smid BE; Rombach SM; Aerts JM; Kuiper S; Mirzaian M; Overkleeft HS; Poorthuis BJ; Hollak CE; Groener JE; Linthorst GE
    Orphanet J Rare Dis; 2011 Oct; 6():69. PubMed ID: 22041095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
    Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
    Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on role of agalsidase alfa in management of Fabry disease.
    Ramaswami U
    Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
    Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
    Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
    Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
    J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
    Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
    PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
    Morel CF; Clarke JT
    Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.